參考資料:
[1]Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system:A retrospective cohort study,Published:February 142022
[2]Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines:A population-based study,Published:December 212021
[3]Ministerio de Salud丨Chile realiza primer estudio a nivel mundial sobre uso de dosis de refuerzo en vacunas inactivadas:Aumenta efectividad en prevención y hospitalización por COVID-19
[4]Pan HX,Wu QH,Zeng G,et al. Immunogenicity and safety of a third dose,and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years:interim results from a double-blind,randomized,placebo-controlled phase 2 clinical trial. medrxiv. 2021.07.23.21261026v1. p>
[5]Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile,September 22021,N Engl J Med 2021; 385:875-884,DOI:10.1056/NEJMoa2107715
[6]新華社丨智利研究稱加强針可大幅提高新冠疫苗有效率
[7]王長征. 新型冠狀病毒肺炎疫苗研究開發現狀和面臨的挑戰[J]. 國際呼吸雜誌,2021,41(17):1281-1285. DOI:10.3760/cma. j.cn131368-20210323-00227. p>
[8]陳維剛. 新冠疫苗是怎樣提供保護作用的[J]. 保健與生活,2021(21):38-39. p>